![Peter Schiemann](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Peter Schiemann is the founder of iQure Pharma Inc. He is currently the Chairman & Chief Executive Officer at Ymmunobio AG.
Aktive Positionen von Peter Schiemann
Unternehmen | Position | Beginn |
---|---|---|
Iqure Pharma, Inc.
![]() Iqure Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Iqure Pharma, Inc. is a biotech company that develops therapeutics for patients and physicians. The company is based in Wilmington, DE. The company was founded by Pawel Zolnierczyk, Henk de Wilde, Peter Schiemann, Anna Rzewuska. Pawel Zolnierczyk has been the CEO since incorporation. | Gründer | - |
Ymmunobio AG
![]() Ymmunobio AG BiotechnologyHealth Technology Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann. | Vorstandsvorsitzender | 01.09.2021 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Iqure Pharma, Inc.
![]() Iqure Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Iqure Pharma, Inc. is a biotech company that develops therapeutics for patients and physicians. The company is based in Wilmington, DE. The company was founded by Pawel Zolnierczyk, Henk de Wilde, Peter Schiemann, Anna Rzewuska. Pawel Zolnierczyk has been the CEO since incorporation. | Commercial Services |
Ymmunobio AG
![]() Ymmunobio AG BiotechnologyHealth Technology Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann. | Health Technology |